Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.

Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N.

PLoS One. 2019 May 14;14(5):e0216954. doi: 10.1371/journal.pone.0216954. eCollection 2019.

2.

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T.

In Vivo. 2018 Nov-Dec;32(6):1587-1590. doi: 10.21873/invivo.11418.

3.

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.

Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.

PMID:
30171175
4.

Nivolumab in non-small-cell lung cancer with EGFR mutation.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T.

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745. No abstract available.

PMID:
29161357
5.

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Tsuji T, Sakamori Y, Ozasa H, Yagi Y, Ajimizu H, Yasuda Y, Funazo T, Nomizo T, Yoshida H, Nagai H, Maeno K, Oguri T, Hirai T, Kim YH.

Oncotarget. 2017 May 16;8(42):71805-71816. doi: 10.18632/oncotarget.17895. eCollection 2017 Sep 22.

6.

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH.

Mol Clin Oncol. 2017 Oct;7(4):677-680. doi: 10.3892/mco.2017.1373. Epub 2017 Aug 11.

7.

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, Funazo T, Nomizo T, Tsuji T, Yoshida H, Nagai H, Ozasa H, Hirai T, Kim YH.

Mol Clin Oncol. 2017 Aug;7(2):295-297. doi: 10.3892/mco.2017.1310. Epub 2017 Jun 29.

8.

EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T.

Anticancer Res. 2017 May;37(5):2721-2725.

PMID:
28476851
9.

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T, Kim YH.

Sci Rep. 2017 Mar 23;7:45124. doi: 10.1038/srep45124.

10.

Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.

Mol Clin Oncol. 2016 Jul;5(1):213-215. Epub 2016 May 6.

11.

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M.

Mol Clin Oncol. 2016 May;4(5):715-718. Epub 2016 Mar 7.

12.

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma.

Tsuji T, Kim YH, Ozasa H, Sakamori Y, Nagai H, Ajimizu H, Yagi Y, Furukawa A, Haga H, Mishima M.

Respir Med Case Rep. 2015 May 15;15:48-50. doi: 10.1016/j.rmcr.2015.05.003. eCollection 2015.

13.

Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed.

Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H, Mishima M.

Mol Clin Oncol. 2015 Mar;3(2):334-340. Epub 2014 Nov 4.

14.

Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.

Kim YH, Nishimura T, Ozasa H, Nagai H, Sakamori Y, Iwata T, Sunadome H, Nishimura T, Mishima M.

Chemotherapy. 2013;59(6):414-9. doi: 10.1159/000363731. Epub 2014 Jul 16.

PMID:
25034625
15.

Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).

Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.

Biomed Rep. 2013 Sep;1(5):691-696. Epub 2013 Jul 22.

16.

Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.

Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.

Case Rep Oncol. 2013 Aug 14;6(2):430-3. doi: 10.1159/000354756. eCollection 2013.

17.

High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y, Nakaoku T, Mishima M.

J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb. No abstract available.

18.

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.

Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1445-51. doi: 10.1007/s00280-013-2142-9. Epub 2013 Mar 27.

PMID:
23532206
19.

Continuous morphine infusion for end-stage lung cancer patients.

Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y, Mishima M.

Oncol Lett. 2013 Mar;5(3):972-974. Epub 2012 Dec 28.

20.

Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer.

Togashi Y, Masago K, Ito Y, Sakamori Y, Okuda C, Fukuhara A, Nagai H, Kim YH, Mishima M.

Oncol Lett. 2013 Feb;5(2):601-604. Epub 2012 Nov 29.

21.

Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.

Masago K, Togashi Y, Fujita S, Nagai H, Sakamori Y, Okuda C, Kim YH, Mishima M.

Oncology. 2013;84(4):214-8. doi: 10.1159/000342854. Epub 2013 Jan 24.

PMID:
23364242
22.

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M.

Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405. doi: 10.1007/s00280-012-1929-4. Epub 2012 Jul 18.

23.

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.

Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12. Review.

24.

Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.

Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.

Int J Oncol. 2012 Jul;41(1):24-30. doi: 10.3892/ijo.2012.1461. Epub 2012 May 2.

PMID:
22552400
25.

Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.

Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K, Mishima M.

Med Oncol. 2012 Dec;29(5):3169-75. doi: 10.1007/s12032-012-0235-7. Epub 2012 Apr 11.

PMID:
22492281
26.

Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.

Sakamori Y, Masago K, Ohmori K, Togashi Y, Nagai H, Okuda C, Kim YH, Ichiyama S, Mishima M.

Cancer Sci. 2012 Jun;103(6):1065-70. doi: 10.1111/j.1349-7006.2012.02249.x. Epub 2012 Apr 15.

27.

Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.

Clin Lung Cancer. 2012 Sep;13(5):385-90. doi: 10.1016/j.cllc.2011.11.009. Epub 2012 Jan 28.

PMID:
22285568
28.

Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.

Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, Nagai H, Kim YH, Mishima M.

Clin Lung Cancer. 2012 Jul;13(4):304-11. doi: 10.1016/j.cllc.2011.11.001. Epub 2011 Dec 13.

29.

Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.

Oncol Rep. 2011 Oct;26(4):795-803. doi: 10.3892/or.2011.1354. Epub 2011 Jun 17.

PMID:
21805046
30.

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.

Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M.

Med Oncol. 2012 Sep;29(3):1614-21. doi: 10.1007/s12032-011-0009-7. Epub 2011 Jul 21.

PMID:
21779929
31.

Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.

Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M.

Clin Lung Cancer. 2011 Sep;12(5):307-12. doi: 10.1016/j.cllc.2011.06.004. Epub 2011 Jul 19.

PMID:
21775215
32.

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1089-92. doi: 10.1007/s00280-011-1691-z. Epub 2011 Jun 17.

33.
34.

Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M.

Oncology. 2010;79(5-6):355-62. doi: 10.1159/000323486. Epub 2011 Mar 24.

PMID:
21430404
35.

Two cases of cancer-associated retinopathy combined with small-cell lung cancer.

Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M.

Jpn J Clin Oncol. 2011 May;41(5):669-73. doi: 10.1093/jjco/hyr025. Epub 2011 Mar 7.

PMID:
21385760
36.

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M.

Lung Cancer. 2011 Oct;74(1):98-102. doi: 10.1016/j.lungcan.2011.01.022. Epub 2011 Mar 5.

PMID:
21377230
37.

EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy.

Kim YH, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.

Oncol Lett. 2011 Mar;2(2):383-387. Epub 2011 Jan 20.

38.

Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients.

Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Kim YH, Mio T, Mishima M.

Oncol Lett. 2011 Mar;2(2):253-256. Epub 2011 Jan 21.

39.

Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity.

Okuda C, Kim YH, Takeuchi K, Togashi Y, Masago K, Sakamori Y, Mio T, Mishima M.

J Thorac Oncol. 2011 Mar;6(3):641-2. doi: 10.1097/JTO.0b013e3182037c80. No abstract available.

40.

Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M.

Clin Lung Cancer. 2011 Jan;12(1):56-61. doi: 10.3816/CLC.2011.n.008.

PMID:
21273181
41.

Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy.

Togashi Y, Kim YH, Masago K, Sakamori Y, Okuda C, Mio T, Mishima M.

Jpn J Clin Oncol. 2011 Apr;41(4):582-5. doi: 10.1093/jjco/hyq244. Epub 2011 Jan 17.

PMID:
21242184
42.

Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer.

Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Mio T, Mishima M.

Oncol Rep. 2011 Feb;25(2):377-82. doi: 10.3892/or.2010.1098. Epub 2010 Dec 10.

PMID:
21165571
43.

Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.

Irisa K, Masago K, Togashi Y, Fujita S, Hatachi Y, Fukuhara A, Sakamori Y, Kim YH, Mio T, Mishima M.

Med Oncol. 2012 Mar;29(1):185-92. doi: 10.1007/s12032-010-9764-0. Epub 2010 Dec 7.

PMID:
21136210
44.

Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab.

Togashi Y, Kim YH, Masago K, Tamai K, Sakamori Y, Mio T, Mishima M.

Int J Clin Oncol. 2011 Aug;16(4):444-6. doi: 10.1007/s10147-010-0148-4. Epub 2010 Nov 30.

PMID:
21116671
45.

Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.

Togashi Y, Masago K, Kubo T, Sakamori Y, Kim YH, Hatachi Y, Fukuhara A, Mio T, Togashi K, Mishima M.

Cancer. 2011 Feb 15;117(4):819-25. doi: 10.1002/cncr.25618. Epub 2010 Sep 30.

46.

Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer.

Fukuhara A, Masago K, Neo M, Fujibayashi S, Fujita S, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Kim YH, Mio T, Mishima M.

Case Rep Oncol. 2010 Mar 24;3(1):63-71.

47.

Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis.

Togashi Y, Kim YH, Miyahara R, Irisa K, Sakamori Y, Masago K, Mio T, Date H, Mishima M.

Tohoku J Exp Med. 2010 Sep;222(1):51-3.

48.

Infectious background of febrile advanced lung cancer patients who received chemotherapy.

Masago K, Fukuhara A, Ito Y, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Fujita S, Kim YH, Mio T, Mishima M.

Oncol Lett. 2010 Sep;1(5):849-853. Epub 2010 Sep 1.

49.

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T, Inui KI, Mishima M.

Case Rep Oncol. 2010 Apr 22;3(2):98-105.

50.

Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.

Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M.

J Thorac Oncol. 2010 Jul;5(7):950-5. doi: 10.1097/JTO.0b013e3181e2138b.

Supplemental Content

Loading ...
Support Center